Compare PAVS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVS | ENTX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 142.0M |
| IPO Year | 2019 | 2018 |
| Metric | PAVS | ENTX |
|---|---|---|
| Price | $2.24 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 6.6M | 140.2K |
| Earning Date | 08-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,416,127.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18037.91 | 25.25 |
| 52 Week Low | $1.38 | $1.50 |
| 52 Week High | $150.00 | $3.22 |
| Indicator | PAVS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 38.38 |
| Support Level | $1.60 | $1.53 |
| Resistance Level | $2.49 | $1.99 |
| Average True Range (ATR) | 0.41 | 0.18 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 57.91 | 37.68 |
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.